Gilead leaning on cancer deals for growth as filgotinib’s future hangs in the balance

As it awaits more clarity on a path forward for autoimmune candidate filgotinib, Gilead is leaning on its recent spate of cancer deals, most notably with ADC developer Immunomedics, for near-term growth. 

Filgotinib, the centerpiece of an ongoing R&D collaboration with Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), had a surprise setback in August when FDA issued a complete response letter for an NDA for 100 and 200 mg doses of filgotinib to treat rheumatoid arthritis (RA). The agency requested data from the Phase II MANTA and MANTA-RAy trials to assess the testicular safety of filgotinib in patients. ...